Cardiac Effects and Management of Stimulant Drug Abuse

Acute Cardiovascular Effects

• Stimulant drugs (cocaine, methamphetamine, amphetamines, MDMA) cause cardiac toxicity through sympathomimetic activation, direct myocardial injury, and ion‑channel blockade. American Heart Association guidelines describe this pathophysiology. 1
• Catecholamine‑reuptake inhibition produces marked tachycardia and hypertension via β‑adrenergic and α‑adrenergic stimulation. American Heart Association recommendation. 1
• Coronary vasospasm can precipitate myocardial ischemia even in the absence of obstructive coronary artery disease. American Heart Association statement. 3
• Acute coronary syndrome (ACS) results from increased myocardial oxygen demand, vasoconstriction‑induced supply reduction, enhanced platelet aggregation, and endothelial dysfunction. American Heart Association evidence. 3
• Wide‑complex tachycardia, QRS/QT prolongation, ventricular tachycardia, and asystolic cardiac arrest occur due to sodium‑ and potassium‑channel blockade. American Heart Association data. 1
• Up to 70 % of methamphetamine users exhibit ECG abnormalities, most commonly tachycardia. American College of Cardiology observational data. 5

Chronic Cardiovascular Complications

• Long‑term stimulant use is associated with dilated cardiomyopathy and progressive myocyte damage. American Heart Association evidence. 3
• Accelerated atherosclerosis has been documented in chronic users. American Heart Association findings. 3
• Methamphetamine use can lead to myocarditis and necrotizing vasculitis. American Heart Association report. 4
• Pulmonary hypertension is a recognized chronic complication of stimulant abuse. American Heart Association statement. 4

Acute Management Strategies

• Benzodiazepines (e.g., lorazepam, diazepam) are first‑line for acute cocaine or methamphetamine intoxication, controlling hypertension, tachycardia, and agitation. American Heart Association recommendation. 3
• Lorazepam or diazepam specifically improve hemodynamics by enhancing GABA_A‑receptor activity inhibited by cocaine. American Heart Association data. 6
• Nitroglycerin (alone or with benzodiazepines) is recommended for hypertension and chest pain related to stimulant toxicity. American Heart Association guideline. 3
• Calcium‑channel blockers are reasonable for severe hypertension or coronary vasospasm when β‑blockers are contraindicated. American Heart Association recommendation. 3
• Phentolamine (α₁‑adrenergic antagonist) is advised for refractory hypertension or vasospasm in acute intoxication. American Heart Association guideline. 1
• Intravenous β‑blockers must be avoided during acute cocaine intoxication because unopposed α‑stimulation can worsen coronary vasospasm. American Heart Association warning. 3
• β‑blockers may be used safely in patients with recent cocaine exposure without acute intoxication signs. American Heart Association conditional recommendation. 3
• Sodium bicarbonate (1 mmol/kg IV bolus, repeat as needed) is reasonable for wide‑complex tachycardia or cardiac arrest caused by cocaine, targeting QRS < 120 ms. American Heart Association guideline. 1
• Lidocaine is reasonable for wide‑complex tachycardia by competitively blocking sodium channels. American Heart Association recommendation. 1
• Rapid external cooling (evaporative or immersive techniques) is recommended for life‑threatening hyperthermia associated with stimulant overdose. American Heart Association statement. 1
• Vasodilators (nitrates, phentolamine, calcium‑channel blockers) are reasonable for cocaine‑induced coronary vasospasm or hypertensive emergencies. American Heart Association guideline. 1
• Management of ACS in cocaine users follows standard ACS protocols, except β‑blockers should be avoided during acute intoxication. American Heart Association recommendation. 3
• For amphetamine/methamphetamine intoxication, the same approach (benzodiazepines, vasodilators, β‑blocker avoidance) is endorsed. American Heart Association guideline. 3

Diagnostic Considerations

• Stimulant use should be suspected in young patients presenting with chest pain or ACS without traditional risk factors. American College of Cardiology clinical insight. 5
• Unexplained tachycardia, hypertension, or arrhythmias warrant evaluation for stimulant exposure. American College of Cardiology recommendation. 5
• The incidence of ACS among cocaine or methamphetamine users is < 10 %, and mortality is rare. American College of Cardiology epidemiologic data. 5
• Urine drug screens become positive 1–4 hours after use and remain detectable for 2–4 days. American College of Cardiology laboratory guideline. 5
• Typical ECG findings include QRS prolongation, QT prolongation, wide‑complex tachycardia, and Brugada‑type patterns. American Heart Association electrocardiographic criteria. 1
• ST‑segment elevation on ECG may indicate vasospastic angina in the context of stimulant use. American Heart Association interpretation. 3

Risk‑Factor Modification

• Smoking cessation is emphasized because concurrent tobacco and cocaine use synergistically heightens cardiovascular risk. Praxis Medical Insights recommendation (only source available). 2